Sanofi and Regeneron received EU approval for broader use of Dupixent in treating chronic obstructive pulmonary disease (COPD), a significant step achieved faster than in the U.S. The EU Commission approved Dupixent for COPD patients not responsive to standard treatments, marking its expanded use beyond conditions like asthma and eczema.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.